HEPHAISTOS-Pharma

Immunotherapies revolutionized the way cancer is treated, bringing an efficient solution to some patients. Unfortunately, 70% of cancer patients are nor eligible or do not respond and relapse.

HEPHAISTOS is developing HEPHA-440, a 3rd generation innate immune booster. Compare to previous generation that were too toxic and limited to intratumoral injection, HEPHA-440 has a controlled safety profile that allows intravenous injection for a systemic effect.

As such, it demonstrated efficacy as single agent both against primary tumors but also against metastases.

Its activation of the innate immune system offers synergies with antibody approaches, such as immune checkpoint inhibitors, but also bispecifics and ADCs. 

We will start the clinical trials in 2027. We are interested in partnering with pharma companies to accelerator the development of our lead candidate.